Results 41 to 50 of about 16,883 (239)

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration

Antimicrobial Agents and Chemotherapy, 2023
Human immunodeficiency virus (HIV) treatment with antiretroviral regimens containing integrase strand transfer inhibitors such as dolutegravir (DTG) and bictegravir (BIC) offers high levels of protection against the development of drug resistance ...
Meng A Xiao, Jenna Cleyle, Sunbin Yoo, Mekayla Forrest, Zoë Krullaars, H. Pham, T. Mesplède   +6 more
semanticscholar   +1 more source

A programmatic assessment of dolutegravir adverse events and discontinuations in Uganda

HIV Medicine
Dolutegravir is now extensively used in sub‐Saharan Africa as a preferred component of antiretroviral therapy (ART). There is a paucity of large studies using routinely collected data from African people living with HIV on dolutegravir‐based regimens to ...
E. L. Odongpiny, M. Nicol, Elizabeth B. Katana, Joseph Owori, Allan Buzibye, Kay Sedan, M. Kesby, Matthew Holden, Noela Owarwo, David Meya, Barbara Castelnuovo, D. Sloan, C. Sekaggya   +12 more
semanticscholar   +1 more source

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks

Open Forum Infectious Diseases, 2023
Background We assessed the efficacy and safety of dolutegravir/lamivudine (DTG/3TC) in a US test-and-treat setting at a secondary 48-week time point of the multicenter, single-arm, phase IIIb STAT study.
Charlotte-Paige Rolle, M. Berhe, Tulika Singh, Roberto Ortiz, A. Wurapa, M. Ramgopal, D. Jayaweera, P. Leone, Jessica Matthews, M. Cupo, M. Underwood, K. Angelis, B. Wynne, D. Merrill, Christopher T Nguyen, J. van Wyk, A. Zolopa   +16 more
semanticscholar   +1 more source

Enhanced Eryptosis Following Exposure to Dolutegravir

Cellular Physiology and Biochemistry, 2016
Background/Aims: The viral integrase enzyme inhibitor dolutegravir is utilized for the treatment of immunodeficiency virus (HIV) infection. Knowledge on cytotoxicity of dolutegravir is limited.
Abdulla Al Mamun Bhuyan, Elena Signoretto, Rosi Bissinger, Florian Lang   +3 more
doaj   +1 more source

Blood glucose level and serum lipid profiles among people living with HIV on dolutegravir-based versus efavirenz-based cART; a comparative cross-sectional study

Annals medicus, 2023
Background Antiretroviral therapy-linked metabolic abnormalities have become a growing concern among people living with HIV. There is limited data regarding the effects of dolutegravir-based treatment on blood glucose levels and serum lipid profiles in ...
Mohammed Jemal, Tewodros Shibabaw Molla, Markeshaw Tiruneh G Medhin, Endeshaw Chekol Abebe, Tadesse Asmamaw Dejenie   +4 more
semanticscholar   +1 more source

Case study: New onset of neuropsychiatric symptoms following switching to a dolutegravir regimen

South African Journal of Psychiatry, 2022
Although reports of neuropsychiatric side effects have been reported with efavirenz, these have been limited in comparison with regard to the now recommended dolutegravir regimens.
Ahmed Badat, Karishma Lowton
doaj   +1 more source

Emergence of Acquired Dolutegravir Resistance in Treatment-experienced People With HIV in Lesotho

Clinical Infectious Diseases
Background Since 2019, the World Health Organization has recommended dolutegravir-based antiretroviral therapy (ART) as the preferred regimen for human immunodeficiency virus management.
Nadine Tschumi, Blaise Lukau, Katleho Tlali, Lipontso Motaboli, Mpho Kao, Mathebe Kopo, Kathrin Hänggi, Moleboheng Mokebe, Klaudia Naegele, Irene Ayakaka, K. Leuzinger, J. A. Brown, N. Labhardt   +12 more
semanticscholar   +1 more source

Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort

Journal of Antimicrobial Chemotherapy, 2023
Background Due to the high prevalence of resistance to NNRTI-based ART since 2018, consolidated recommendations from the WHO have indicated dolutegravir as the preferred drug of choice for HIV treatment globally.
A. Abdullahi, I. Kida, U. A. Maina, A. Ibrahim, J. Mshelia, H. Wisso, A. Adamu, J. Onyemata, M. Edun, H. Yusuph, S. Aliyu, M. Charurat, A. Abimiku, Lucie Abeler-Dorner, C. Fraser, D. Bonsall, S. Kemp, Ravindra K. Gupta   +17 more
semanticscholar   +1 more source

Pharmacokinetics of dolutegravir, tenofovir and lamivudine during venous–venous extracorporeal membrane oxygenation (VV‐ECMO): A case report

British Journal of Clinical Pharmacology, EarlyView.
While providing potentially life‐saving cardiorespiratory support for critically ill patients, extracorporeal membrane oxygenation (ECMO) may detrimentally affect pharmacokinetic (PK) performance and concurrent drug efficacy and safety. We describe a patient with Pneumocystis jirovecii pneumonia (PJP) in the context of acquired immunodeficiency ...
Tom C. Zwart, Emiel Leegwater, Thomas H. Ottens, Emile F. Schippers, Erik B. Wilms, David M. Burger, Cees van Nieuwkoop, Liesbeth B. E. Bosma   +7 more
wiley   +1 more source

Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus

SAGE Open Medical Case Reports, 2022
HIV-infected people have started to live longer since the introduction of antiretroviral therapy, however various co-morbid illnesses have emerged. Three HIV-infected individuals, all at least 43 years old, reported with a new onset of type 2 diabetes ...
Agete Tadewos Hirigo, Selamawit Gutema, Aberash Eifa, Worku Ketema   +3 more
doaj   +1 more source